Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision facing companies developing biologics products, such as cell and gene therapies, where technologies are...more
11/15/2024
/ Biologics ,
Business Model ,
Damages ,
Discovery ,
Food and Drug Administration (FDA) ,
Healthcare ,
Injunctive Relief ,
Life Sciences ,
Non-Disclosure Agreement ,
Patent Infringement ,
Patent-Eligible Subject Matter ,
Patents ,
Reverse Engineering ,
Trade Secrets
The Affordable Prescriptions for Patients Act (APPA) of 2023 unanimously passed the Senate on July 11, 2024. The APPA was first introduced to the House on January 30, 2023 by Representative John Cornyn (R-Tx), with the aim of...more
In ChromaDex Inc. v. Elysium Health Inc., the Federal Circuit found U.S. Patent No. 8,197,807 (the “’807 patent”), which is directed to a dietary supplement comprising an isolated vitamin, invalid for lack of subject matter...more
If your limited attention is diverted this week because of March Madness, never fear! We’ve got you covered at Federal Circuitry, where we’re always tracking the latest news at the Federal Circuit. Below we provide our usual...more